Central Nervous System Miliary Brain Metastasis Secondary to Breast Cancer

Gabriel Santos Vázquez, Ricardo García Cázarez, Erick Moreno Pizarro, Aarón Emanuel Serrano Padilla, Juan Carlos Plascencia Salcedo

Received 06/16/2020
Review began 06/24/2020
Review ended 07/24/2020
Published 08/10/2020

Corresponding author: Aarón Emanuel Serrano Padilla, aaron.serrano@outlook.com

Abstract

Miliary metastasis to the central nervous system (CNS) is a rare presentation of metastasis mainly found in primary adenocarcinoma of the lung. Its association with breast cancer is even less frequent. We present the case of a 50-year-old female patient diagnosed in 2010 with stage IIA infiltrating ductal breast cancer RE (-), RP (+), HER 2 (-), HER2 NEU (+). She was treated with modified radical left breast mastectomy, radiation therapy, and chemotherapy. Her condition began presenting oppressive frontal headache without irradiation, predominantly in the evening, intensity 8/10, which decreased when sleeping and was exacerbated with stressful situations, in addition to progressive cognitive deterioration. Simple and contrasted computed tomography (CT) of the skull and thoracoabdominal were requested, showing multiple micronodular lesions with calcium density in the brain parenchyma, left pleural effusion, hypo and hyperdense lesions in the liver parenchyma, as well as osteoblastic lesions in the lumbar spine. Simple and contrasted magnetic resonance imaging (MRI) of the skull showed multiple supra and infratentorial intra-axial lesions. The most frequent associated symptom with miliary metastasis is cognitive impairment. Miliary metastasis, confirmed by imaging studies and histopathology, requires the ruling out of other causes of this calcification pattern, such as neurocysticercosis, due to specific treatment for each pathology.

Introduction And Background

Miliary metastasis was first described in 1951 as "carcinomatous encephalitis." It was described as multiple plaques formed from perivascular distribution [1]. It is a rare presentation in breast cancer. At this time, its mechanism of occurrence is not fully known [2-3]. Physiological (pineal gland, choroid plexus, habenula, falx cerebri, tentorium, among others), and pathological (tuberculosis, cystercerosis, TORCH (Toxoplasma gondii, others (including Treponema pallidum, Listeria, Varicella, and parvovirus B19), rubella virus, cytomegalovirus (CMV), and herpes simplex virus (HSV)) disease, chronic viral encephalitis, Fahr’s disease, thyroid or parathyroid disease) [4] calcifications could complicate the clinical diagnosis of miliary metastasis since they present with similar symptoms such as hemiparesis, dysarthria, short/long-term memory loss, seizures, language abnormalities, ataxia, dementia, psychosis, or headache [2,5]. The objective of this work is to describe a case of central nervous system miliary metastasis secondary to breast cancer, as well as a literature review on this topic.
Patients and methodology

A literature review of both English and Spanish was performed in the Medline databases using the following keywords: “miliary calcifications brain”, “miliary brain metastases”, “metastatic breast cancer”, and “miliary brain calcifications”, as well as their respective keywords in Spanish. Independent of the primary tumor strain, all case reports since 1988 to 2019 on miliary brain metastases in the central nervous system, were selected and their clinical characteristics described. Likewise, a patient’s case was reported and sent to the neurology service of our unit, where this diagnosis was made.

Review

Case presentation

A 50-year-old female nurse, with genetic load for diabetes mellitus, denied smoking and drug use, occasional alcoholism, and allergic to sulfonamides. She denied chronic-degenerative diseases, transfusions, or trauma-related conditions. She was diagnosed with breast cancer in 2010, treated with a modified radical mastectomy of the left breast. Histological variety described as an invasive ductal carcinoma stage IIA RE (-), RP (+), HER 2 (-), HER2 NEU (+). She was administered adjuvant chemotherapy with anthracyclines and taxanes sequentially, eight cycles, 25 sessions of radiotherapy, tamoxifen for five years, with extended adjuvant anastrozole and exemestane to date.

Symptoms began on July 30, 2019, as she described an acute frontal headache without irradiation, predominantly in the evening, intensity 8/10. It decreased while sleeping and exacerbated with stressful situations, without other accompanying symptoms. On August 5, 2019, she attended her checkup at the oncology medical visit, commenting on her symptoms. In addition, the physical examination noted disorientation in time and space and a language disorder being inconsistent and inappropriate. It was decided to hospitalize her for the complete study protocol. Regarding the initial exploration, her vital signs were within normal parameters, normocephalus, without obvious lesions, rhythmic precordium without murmurs, left basal hypoventilation without crackles, and decreased vocal resonance. Abdomen and limbs were without abnormalities.

Upon neurological examination, the patient showed alterations in mental state, with disorientation in time and space. Folstein's mini-mental test was 19/30, with impaired memory, abstraction, judgment, and language. Cranial nerve examination showed no abnormalities. There was motor function with preserved tone and trophism in all extremities, strength was 4/5 proximal and distal in the right arm, 5/5 in all the others. Deep tendon reflexes were ++/++++ and the Babinski sign was negative. The sensory system was not objectively evaluated due to the mental state of the patient. The cerebellar function showed bilateral eumetry and eudiadocinesia, without pathological nystagmus, as well as normal gait. There were no meningeal irritation signs. Pathologic reflexes were present: sucking, palmamental, and grasping.

The patient was admitted with a diagnosis of an acute confusional state. A simple and contrasted CT scan of the skull was performed, showing multiple micronodular lesions in the entire cerebral parenchyma, both white and gray matter, without meningeal enhancement. (Figure 1, Appendix 1). Complementary tests showed hematic cytometry, blood chemistry of three elements, serum electrolytes, and thyroid function test within normal parameters. Liver function tests reported total bilirubin 0.3 mg/dL, conjugated bilirubin 0.3 mg/dL, aspartate aminotransferase (AST) 43 U/L, alanine transaminase (ALT) 52 U/L, gamma-glutamyl transferase (GGT) 158 U/L, alkaline phosphatase 100 U/L, albumin 3 g/dL, parathormone levels 22.7 pg/mL (4-58.1). The cerebrospinal fluid analysis was reported as acellular, the acid-fast...
Bacillus (AFB) test was negative, cysticercus antigen was negative, proteins 50 mg/dL. The serology was as follows: CMV immunoglobulin G (IgG) >180, CMV IgM <5, toxoplasmosis IgG 22.5, toxoplasmosis IgM <3, rubella IgG 13.8, and rubella IgM 11.7. Anti-HIV 1 and 2 (anti-human immunodeficiency virus 1 and 2) were negative, hepatitis C was negative, and hepatitis B surface antigen was negative. With these results and due to the clinical presentation dexamethasone was started.

**FIGURE 1: Transverse cerebral CT scan**

Red arrows in A-D: Micronodular lesions with calcium density distributed throughout the brain parenchyma. With gray and white substance affection.

CT: computed tomography

Simple and contrasted thoracoabdominal CT was requested, which showed left pleural effusion, multiple hypodense hepatic lesions with contrast, as well as osteoblastic lesions at the lumbar spine level (Figure 2). MRI of the skull showed multiple intra-axial supra and infratentorial lesions with gadolinium enhancement in the T1 sequence (Figure 3).

**FIGURE 2: Abdominal CT scan with corresponding images of metastatic lesions**

A: Multiple hypo- and hyperdense lesions distributed in the liver parenchyma (red arrows), as well as left basal pleural effusion (blue arrow); B: Hyperdense lesion at the L1 level (red arrow)

CT: computed tomography
The patient was treated with prophylactic anticonvulsants and antiedema steroids and was transferred to a tertiary center to receive holocranial radiotherapy.

Discussion

Breast cancer is the most common cancer in women in the United States. In 2018, the World Health Organization (WHO) estimated that it affects 2.1 million women each year, 627,000 women died of breast cancer, in addition to it accounting for 15% of all cancer deaths among women. Nearly 30% of new breast cancer diagnoses have already spread to regional lymph nodes and 5% of these occur with metastases at the time of presentation, with the median age of diagnosis being at 50 years [5-6]. Breast cancer can be classified by microarray techniques into several intrinsic subtypes: luminal A, luminal B, enriched with HER2, and triple-negative [7]. Central nervous system (CNS) metastasis is most frequently observed in the following subtypes of breast cancer: Triple-negative, shows a higher incidence of visceral and cerebral tumor metastasis (46%), HER2-positive (5-30%), as well as TP-53 positive; the last one of these was reported with a 38% higher probability of occurrence as compared to TP-53 negative [5-6]. Metastatic lesions have been related to the initial site of appearance; it is more common after initial metastasis to the bone (26.7%). Once pleural metastasis has been established, the disseminated disease is more common, including CNS compromise in 63.6% [8].

There have been 26 cases of miliary metastasis to the CNS reported to date. The most frequent primary tumor was lung (61.54%), followed by breast and unknown origin, with 11.54% each.

The clinical presentation of miliary metastasis to the CNS is heterogeneous, the most frequent symptoms, in general, were cognitive impairment in 28%. In patients with primary breast tumors, the most frequent symptoms were psychiatric alterations and language disorders.

To date, the most associated cancer with military metastasis to the central nervous system is lung cancer. The importance of our case report lies in the rarity of its association and the clinical description of its manifestations. From all the reported cases, this is the third worldwide with a primary origin in the breast. Besides, the most frequent symptomatology has been described according to each lineage to date.

Among the differential diagnoses to be considered in our population are neurocysticercosis and CNS tuberculosis, however, clinically, the first one usually presents with epilepsy, while
tuberculosis tends to manifest more frequently as basal arachnoiditis, affecting the lower cranial nerves [9-10]. In consideration of these findings, data from CT, MRI, and cerebrospinal fluid (CSF) study, we excluded these diagnostic possibilities.

Table 1 lists the 26 cases of miliary metastasis to the CNS while Table 2 lists the frequency of the primary origin of miliary metastasis to the CNS.

| Reference and year | Gender and age | Primary tumor site | Histological variant | Symptoms |
|--------------------|----------------|--------------------|----------------------|----------|
| Madow and Alpers (1951) [1] | 55/M | Lung | Adenocarcinoma | Psychiatric Hemiparesis Aphasia Convulsions |
|                    | 48/M | Unknown | Adenocarcinoma | Psychiatric Convulsions |
|                    | 47/M | Lung | Adenocarcinoma | Psychiatric Hemiparesis Convulsions |
| Fukuda et al (1988) [11] | 31/F | Lung | Adenocarcinoma | Headache Convulsions Psychiatric |
| Ara Callizo et al (1989) [12] | 60/F | Lung | Adenocarcinoma | Hemiparesis Cognitive impairment |
| Nemzek et al (1993) [13] | 61/M | Pancreas | Acinar Cell Carcinoma | Confusion Hemiparesis |
| Yamazaki et al (1993) [3] | 59/F | Lung | Small cell carcinoma | Bradysychia Convulsions |
| Shirai et al (1997) [14] | 58/M | Lung | Adenocarcinoma | Cognitive Impairment Hemiparesis |
| Bushan et al (1997) [15] | 68/M | Neck (salivary gland) | Adenocarcinoma | Headache Hemiparesis |
| Rivas et al (2005) [18] | 75/M | Lung | Adenocarcinoma | Cognitive Impairment Convulsions |
| Ota et al (2006) [19] | 79/F | Unknown | Adenocarcinoma | Visual Hallucinations Extrapyramidal Symptoms |
| Ogawa et al (2007) [17] | 82/F | Lung | Adenocarcinoma | Psychiatric |
| Iguchi et al (2007) [20] | 66/M | Lung | Adenocarcinoma | Cognitive Impairment |
| Inomata et al (2012) [21] | 68/F | Lung | Adenocarcinoma | Headache Ataxia |
| Kahveci et al (2012) [22] | 52/M | Lung | Adenocarcinoma | Poor Cooperation |
| Bekiesinska et al (2013) [23] | 52/M | Lung | Adenocarcinoma | Cognitive Impairment |
Dumoulin et al (2015) [24] 58/M Lung Adenocarcinoma Cognitive Impairment
Zhang et al (2016) [25] 3/F Cerebellopontine Angle Teratoid rhabdoid tumor Facial Paralysis Hearing Impairment
27/M Thalamus Glioma Facial Paralysis Hearing Impairment
de Ceuster et al (2016) [26] 38/F Breast Unspecified Dysarthria Ataxia
Cools et al (2019) [2] 48/F Breast Unspecified Hallucinations Delirium Aphasia
Kurihara et al (2019) [27] 74/F Lung Adenocarcinoma Cognitive Impairment Akinetic Mutism
The case reported in this review (2020) 50/F Breast Invasive Ductal Headache Cognitive Impairment

TABLE 1: Cases reported in the literature to date of miliary metastasis to the central nervous system
F: female; M: male

| Primary site            | Frequency % (n) |
|------------------------|-----------------|
| Lung                   | 61.54 (16)      |
| Breast                 | 11.54 (3)       |
| Unknown                | 11.54 (3)       |
| Thalamus-pontine       | 7.69 (2)        |
| Pancreas               | 3.85 (1)        |
| Neck                   | 3.85 (1)        |
| Total                  | 100 (26)        |

TABLE 2: Frequency of primary origin of miliary metastasis to the central nervous system

The main weakness of our study was the lack of a confirmatory histopathological study. However, the most relevant differential diagnoses were excluded.

Conclusions

CNS metastases are common among cancers. Miliary metastasis is rare, with breast cancer being even less common. Therefore, its finding requires differential diagnoses with other...
entities, which radically changes the treatment and prognosis of these patients.

Appendices

Appendix 1

FIGURE 4: Cerebral transversal CT scan (20 slices)

Micronodular lesions throughout all the brain parenchyma

CT: computed tomography

Additional Information

Disclosures
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: Following the request that was made to our article, we have already addressed the ethical background behind our paper via email, permission by our patient was given to us, so we checked the box that states that we dont have any ethical trouble. Feel free to contact us at any time, we thank you for the time given to review our paper.

References

1. Madow L, Alpers BJ: Encephalitic form of metastatic carcinoma. AMA Arch Neurol Psychiatry. 1951, 65:161-173. 10.1001/archneurpsyc.1951.02320020033003
2. Cools D, Parizel PM, Dekeyzer S: Miliary brain metastases from primary breast carcinoma: a case report. Acta Neurol Belg. 2019, 120:175-176. 10.1007/s13760-019-01092-9
3. Yamazaki T, Harigaya Y, Noguchi O, Okamoto K, Hirai S: Calcified miliary brain metastases with mitochondrial inclusion bodies. J Neurol Neurosurg Psychiatry. 1993, 56:110-111. 10.1136/jnnp.56.1.110
4. Sedghizadeh PP, Nguyen M, Enciso R: Intracranial physiological calcifications evaluated with cone beam CT. Dentomaxillofacial Radiol. 2012, 41:675-678. 10.1259/dmfr/33077422
5. Chikarmane SA, Tirumani SH, Howard SA, Jagannathan JP, DiPiro PJ: Metastatic patterns of breast cancer subtypes: what radiologists should know in the era of personalized cancer medicine. Clin Radiol. 2015, 70:1-10. 10.1016/j.crad.2014.08.015
6. Savci-Heijink CD, Halfwerk H, Hooijer GK, Horlings HM, Wesseling J, van de Vijver MJ: Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res Treat. 2015, 150:547-557. 10.1007/s10549-015-3352-0
7. Anders CK, Carey LA: Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009, 9:73. 10.3816/CBC.2009.s.008
8. Cummings MC, Simpson PT, Reid LE, et al.: Metastatic progression of breast cancer: insights from 50 years of autopsies. J Pathol. 2014, 232:23-31. 10.1002/path.4288
9. Coyle CM: Neurocysticercosis: an individualized approach. Infect Dis Clin. 2019, 33:153-168. 10.1016/j.idc.2018.10.007
10. Zunt JR: Tuberculosis of the central nervous system. Contin Lifelong Learn Neurol. 2018, 24:1422-1438. 10.1212/CON.0000000000000648
11. Fukuda Y, Homma T, Kohga H, Uki J, Shisa H: A lung cancer case with numerous calcified metastatic nodules of the brain. Neuroradiology. 1988, 30:265-268. 10.1007/BF00341841
12. Callizo JA, Gimenez-Mas JA., Martin J., Lacasa J: Calcified brain metastases from acinar-cell carcinoma of pancreas. Neuroradiology. 1989, 31:200. 10.1007/BF00698858
13. Nemzek W, Poirier V, Salamat MS, Yu T: Carcinomatous encephalitis (miliary metastases): lack of contrast enhancement. Am J Neuroradiol. 1993, 14:540-542.
14. Shirai H, Imai S, Kajihiro Y, et al.: MRI in carcinomatous encephalitis. Neuroradiology. 1997, 39:457-440. 10.1007/s002340050441
15. Bhushan C: "Miliary" metastatic tumors in the brain: case report. J Neurosurg. 1997, 86:564-566. 10.3171/jns.1997.86.3.0564
16. Nakamura H, Toyama M, Uezu K, Nakamoto A, Toda T, Saito A: Diagnostic dilemmas in oncology. Case 1. Lung cancer with miliary brain metastases undetected by imaging studies. J Clin Oncol. 2001, 19:4340-4341.
17. Ogawa M, Kurahashi K, Ebina A, Kaimori M, Wakabayashi K: Miliary brain metastasis presenting with dementia: progression pattern of cancer metastases in the cerebral cortex. Neuropathology. 2007, 27:390-395. 10.1111/j.1440-1789.2007.00782.x
18. Rivas E, Sanchez-Herrero J, Alonso M, et al.: Miliary brain metastases presenting as rapidly progressive dementia. Neuropathology. 2005, 25:153-158. 10.1111/j.1440-1789.2005.00595.x
19. Ota S, Tsuchiya K, Anno M, Akiyamat H: An autopsy case of miliary brain metastases [Article in Japanese]. No To Shinkei. 2006, 58:161-165.
20. Iguchi Y, Mano K, Goto Y, et al.: Miliary brain metastases from adenocarcinoma of the lung: MR imaging findings with clinical and post-mortem histopathologic correlation.
21. Inomata M, Hayashi R, Kambara K, et al.: Miliary brain metastasis presenting with calcification in a patient with lung cancer: a case report. J Med Case Reports. 2012, 6:279. 10.1186/1752-1947-6-279

22. Kahveci R., Gürer B., Kaygusuz G., Sekerci Z: Miliary brain metastases from occult lung adenocarcinoma: Radiologic and histopathologic confirmation. J Neurosci Rural Pract. 2012, 3:386-389.

23. Bekiesińska-Figatowska M, Kuczyńska-Zardzewialy A., Klepacka T, et al.: Miliary brain metastases from papillary adenocarcinoma of the lung-unusual MRI pattern with histopathologic correlation. Pol J Radiol. 2013, 78:57. 10.12659/PJR.889182

24. Dumoulin J, Rozensztajn N, Paradis M, et al.: Miliary cerebral carcinomatosis secondary to EGFR mutation-positive lung adenocarcinoma [Article in French]. Rev Mal Respir. 2016, 33:67-71. 10.1016/j.rmr.2015.01.003

25. Zhang M, Wang Z, Zhang J, et al.: Metastases in cerebellopontine angle from the tumors of central nerve system. J Clin Neurosci. 2017, 42:84-90. 10.1016/j.jocn.2017.04.011

26. de Ceuster LM, de Bruijn SF, Hoffmann CF: Miliary cerebral calcifications: a rare presentation of breast cancer metastasis. Neurology. 2016, 86:879-879. 10.1212/WNL.0000000000002424

27. Kurihara M, Koda H, Anno H, et al.: Rapidly progressive miliary brain metastasis of lung cancer after EGFR tyrosine kinase inhibitor discontinuation: an autopsy report. Neuropathology. 2019, 39:147-155. 10.1111/neup.12542